Background and Aims Methadone patients who discontinue treatment are at high risk of relapse, yet a substantial
INTRODUCTION
In the treatment of heroin addiction, longer retention in methadone maintenance is associated with reduced opioid use as measured by urine screens and other positive outcomes [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] , yet many patients leave methadone treatment within 12 months of admission [13] [14] [15] [16] [17] . A systematic review of low-and middle-income countries found average 12-month retention rates of 56%, and a 50% rate in high-income countries was considered a benchmark for success [14] . In the United States, methadone treatment is provided solely through specially regulated methadone treatment programs (MTPs) that require some level of counseling. In these programs, some practices can lead to decreased retention, including 'administrative' discharge for failure to comply with various program rules, such as fee payment, counseling attendance, repeated positive drug tests and loitering [18] [19] [20] . Typically, prior to actual administrative discharge, conflicts with staff can lead to patients leaving treatment [20] . In many MTPs the counselor functions as the disciplinarian, a role in potential in conflict with maintaining a therapeutic alliance. An additional factor in premature discharge is the lack of continuation of methadone treatment during brief incarcerations [21, 22] .
Patient-centered care is 'respectful of and responsive to individual patient preferences, needs, and values' [23, 24] . It stems from the patient-provider relationship [25] and should permit patients to exercise control over their health-care decisions. The present study tested the effectiveness of an approach to methadone treatment based on these principles. We sought to reduce program-related reasons for premature and administrative discharge (e.g. counseling non-attendance and rule infractions) and hence to reduce opioid use and improve other participant outcomes by changing some of the rules and staff roles. This study addressed whether patient-centered treatment compared to methadone treatment-as-usual (TAU) would be associated with lower rates of opioid-positive urine screens and a variety of secondary outcomes at 12-month follow-up.
METHODS

Design
This was a two-parallel-groups clinical trial in which newly admitted methadone patients were assigned randomly on a 1 : 1 basis to PCM or TAU. Participants were evaluated at study entry and at 3, 6-and 12-month follow-up.
Participants
Participants were newly admitted methadone patients aged 18 years and over who provided informed consent, passed an eligibility quiz and were not pregnant. Followup interviews were conducted between 20 December 2011 and 1 April 2015.
Study sites
The study was conducted at two non-profit MTPs in Baltimore, each with a census of approximately 500 patients of lower socio-economic status.
Recruitment
Research assistants (RAs) recruited patients shortly after admission through referral from MTP staff. The RAs screened for eligibility and offered informed consent in a private office at the MTP. Recruitment began on 13 September 2011, and the target of 300 participants was reached on 26 March 2014. The Institutional Review Boards (IRBs) of Friends Research Institute and the participating programs approved the study, which had a Data and Safety Monitoring Board.
Interventions (treatment conditions)
Prior to launch, the participating MTPs each had two treatment teams led by senior counselors. At study initiation, within each MTP, team leaders decided which one would provide PCM for study participants. Some elements of treatment remained common to both conditions, including: psychosocial and medical intake, dose induction, drug screening and methadone take-home eligibility.
Treatment-as-usual
TAU was the same treatment offered to patients not enrolled into the study. Participants were required to attend individual and/or group counseling as determined by their counselor. The counselors were both therapists and disciplinarians. Additionally, they served as contact for program services.
Patient-centered methadone (PCM)
One team at each clinic accepted participants assigned to PCM. In keeping with the definition of patient-centered treatment in which treatment is tailored to the patients' preferences and need, these participants (in contrast to TAU) were encouraged but not required to attend individual and/or group counseling as often or as little as they preferred. In keeping with the goal of enhancing the patient provider relationship, their counselors served solely as therapists. The PCM team leaders would meet with participants as necessary to address rule-related issues. The RA provided a summary of the modified clinic rules to these participants after random assignment. They were required to have one introductory meeting with their counselor, who would review the modified rules with them. Counselors were able to advocate on their participants' behalf regarding rule violations.
A number of TAU clinic rules were also altered. For example, PCM participants were not to be discharged 'administratively' for rule infractions such as: missing counseling; and/or a specified number of consecutive days of treatment; failure to pay fees (which were typically minimal); loitering; verbal conflicts with other patients or staff; or providing adulterated urine specimens. In response to these situations, graduated consequences as an alternative to administrative discharge were sought. For example: counseling was voluntary; participants could be reinstated after missing medication; alternative payment accommodations were encouraged; loitering was to be handled by permitting PCM participants extra leeway to remain in the clinic waiting room; verbal conflicts were handled where possible through remediation by the team leader; and adulterated urine specimens were simply considered a presumptive positive.
Fidelity
A number of steps were taken to enhance fidelity to the assigned treatment condition. The Principal Investigator (PI) trained each team on their aspects of the protocol separately and held monthly PCM team meetings to review cases for fidelity. Based on counselor reports and RAs review of progress notes, any issues related to possible confounds were discussed and clarified. At the conclusion of the study, the RAs undertook a structured record review of every participant record to determine whether counselors adhered to the study protocol. This review used a checklist that mirrored the items in Table 1 .
Study procedures and measures
Randomization
Within each MTP, participants were assigned randomly to either TAU or PCM using block randomization based on successive random permutations of the sequence 1 : 1 : 2 : 2, such that for each successive block of four participants, two were assigned to each condition. Numbered, opaque envelopes containing assignments were prepared for each site by the project manager. After completing the baseline assessment, RAs opened the next numbered envelope to determine the assigned condition.
The RA administered the assessments described below at baseline, 3-, 6-and 12-month follow-up for which the participants were paid $30 each.
Primary outcome at 12-month follow-up
The primary outcome measure was percentage of opioidpositive urine tests conducted by the RA (using a dip test: DrugCheck ® NxStep Onsite Drug Screen Cup) at 12 months. The RA informed participants of the test results prior to commencing their interviews to maximize the likelihood of accurate self-report of recent drug use. Urine specimens were also sent to a laboratory for EMIT testing.
Secondary outcomes at 12-month follow-up Table 1 Number of participants and number of times topic discussion occurred with participants by counselors and counselor supervisors (n = 295). illegal substance use section (WMH-CIDI [27] ). An expanded prior version of that section (the CIDI substance abuse module) was found to have good reliability in diagnosing both African American and Caucasian respondents with opioid and cocaine dependence (kappa values: 0.63-0.77 [28] . 4 HIV drug and sex risk scores were obtained from the HIV Risk Assessment Battery (RAB), composed of 45 questions covering substance and needle use and sexual risk behaviors in the past 6 months [7] . 5 Quality of Life Global Scores were obtained from the single item of the World Health Organization Quality of Life Scale-Brief (WHOQoL-BREF): 'How would you rate your quality of life' rated by participants on a scale of 1 (very dissatisfied) to 5 (very satisfied) [29, 30] . 6 Aggregate Physical and Mental Health Quality of Life Score were obtained from the Short Form-12, version 2 [31] , an abbreviated version of the SF-36 which is widely used to measure physical and mental health status. The aggregate physical and mental health scales are scored using norm-based methods and scores are standardized. Test-retest reliability for the scales were found to be high in US populations (0.89 for physical and 0.76 for mental health). 7 Treatment retention in the original opioid treatment program (OTP) was measured from program records and in any other OTP or buprenorphine treatment from self-report.
PCM (n
Other measures
Therapeutic alliance
Therapeutic alliance was measured using the Helping Alliance Questionnaire (HAQ-II), a 19-item instrument used to measure the therapeutic alliance [32] . The HAQ-II responses on its 19 items each have six possible responses ranging from 1 (strongly disagree) to 6 (strongly agree) [32] . In its validation study, Cronbach's alpha reliability scores ranged from 0.90 to 0.93 [32] . HAQ-II scores were analyzed for participants who reported attending three or more counseling sessions prior to each follow-up interview (n = 190, 156 and 151 at 3, 6 and 12 months, respectively).
Patient satisfaction with the program and counselor
Patient satisfaction with the program and counselor was measured with the self-report Client Evaluation Form (CEF), that inquires about the participants' views of treatment satisfaction, treatment needs and counselor services [33, 34] . The CEF consists of 23 self-rated items scored on a five-point Likert scale, with 5 indicating the most positive rating [33, 34] . Counselor services scores were analyzed for participants who reported attending three or more counseling sessions prior to each follow-up interview.
Number of counseling sessions attended
Number of counseling sessions attended, by individual and group subtype, was collected by RAs from the participant's MTP record.
Methadone dose
Methadone dose was collected from the participant's record at each follow-up due date.
Data analysis
Sample size
Based on findings from our earlier trial of interim methadone maintenance [35] , we expected that the TAU group would have a 46% rate of opioid-positive urine screening test results at the 12-month end-point. We calculated that we would need a sample size of 300 participants to yield 80% power to detect a 30% difference in opioid-positive urine screening tests results favoring the PCM group (that is, a 32% opioid-positive urine screening test result in the PCM group), corresponding to an odds ratio of 1.79, using a two-sided Type I error rate of 5%).
Generalized linear mixed models analysis was used to compare the primary outcome of 12-month opioidpositive urine screening between PCM and TAU. The same approach was used to compare the 12-month outcomes for all secondary outcome variables listed above. Days of heroin and cocaine use in the past 30 days and methadone dose were assumed to follow a Poisson distribution; RAB drug-and sex-risk scores, WHOQoL-BREF global question scores, SF-12 version 2 aggregate physical and mental health scores, HAQ-II scores and CEF patient satisfaction scores were assumed to follow a normal distribution; and DSM-IV opioid and cocaine dependence, opioid and cocaine urine screenings and retention were assumed to follow a binomial distribution. MTP site was treated as a random effect, and missing data for opioid and cocaine urine tests were considered positive. For all other variables (except methadone dose, HAQ-II and CEF), baseline values were used where 12-month data were missing.
An additional preplanned analysis examining changes in all the above-mentioned outcome variables over time (baseline, 3-, 6-,and 12-month follow-ups) was conducted using a generalized estimating equations (GEE) approach. This analysis was considered important, because participant outcomes over the entire course of treatment (not just at a fixed point in time) are of clinical importance.
RESULTS
Participants
As shown in Fig. 1 , 406 newly admitted patients were assessed for eligibility, of whom 21 did not meet inclusion criteria and 85 refused participation. Three hundred patients provided informed consent and were assigned randomly (149 to PCM and 151 to TAU). Shortly after randomization, five participants were deemed ineligible (two had transferred from another MTP, one with psychosis, one with severe benzodiazepine dependence and one was enrolled into the study previously at the other site), leaving 295 evaluable participants (146 in PCM and 149 in TAU). At 3-, 6-and 12-month follow-up assessments, 97.6, 97.3 and 96.9% of the 295 participants were located, and 90.2, 86.4 and 82.4% were interviewed.
Patient baseline characteristics are shown in Table 2 . The sample was 59% male, 58% African American and 41% white, with a mean [standard deviation (SD)] age of 42.7 (10.1) years.
Outcomes
Primary outcome
As shown in Table 3 , there was no significant difference between study condition for the percentage of participants with opioid-positive urine screens at 12-month follow-up [61.0% PCM, 60.4% TAU; difference = 0.6%, 95% confidence interval (CI) = À0.11 to 0.12 %; P = 0.92].
Secondary outcomes
No significant differences by study condition were found for secondary outcome variables of cocaine-positive urine screens, self-reported heroin and cocaine use, meeting DSM-IV opioid and cocaine dependence criteria, HIV risk behaviors, aggregate physical and mental health quality of life or treatment retention at 12 months (all Ps > 0.05; Table 3 ). For Quality of Life Global Score, PCM participants reported a significantly higher mean score than TAU participants (means = 3.70 and 3.47 for PCM and TAU, MTP = methadone treatment program; SD = standard deviation. There were no statistically significant differences between treatment conditions on any variables (all Ps > 0.05), except for life-time number of arrests (P = 0.01); n = 291 (145 PCM, 146 TAU) rather than 295 for age of first heroin use due to four participants who reported never having used heroin; n = 249 (122 PCM, 127 TAU) for age of first cocaine use due to 46 participants who reported never having used cocaine; n = 272 (136 PCM, 136 TAU) for age of first crime due to 23 participants who reported never having committed a crime. respectively; difference = 0.23, 95% CI = 0.01-0.45; P = 0.04).
Other outcomes
Counseling attendance
There were no significant differences found between conditions in the mean number of individual (means = 8.69 and 7.77 for PCM and TAU, respectively) and group counseling sessions attended over the 12 months (Ps > 0.05), although the PCM condition attended a mean of 3.77 sessions versus 6.35 for the TAU condition.
Methadone dose
The PCM condition had a significantly lower mean methadone dose than the TAU condition at 12 months (means = 70.8 and 76.6 for PCM and TAU, respectively; difference = À5.93, 95% CI = À11.33 to À0.52; P = 0.03).
Therapeutic alliance and patient satisfaction
There were no significant differences between conditions in therapeutic alliance or patient satisfaction scores at 12 months (all Ps > 0.05)
Fidelity to the PCM model
Fidelity to the PCM model is shown in Table 1 . The major difference between treatment conditions was that TAU counselors noted discussing counseling attendance requirements with 42 participants a total of 94 times, in contrast to the PCM counselors, who noted discussing this requirement with only nine participants a total of 17 times. TAU counselors discussed other rule violations with seven participants a total of seven times, but there were no such discussions noted by PCM counselors. There were few notes regarding supervisors' discussions with participants. Finally, there were relatively few threats of involuntary discharge in either treatment condition.
Deaths and hospitalizations
There were four non-study-related deaths in TAU (one each for pneumonia and vascular disease complicated by cocaine use) and two overdoses (one from heroin, methadone, dextromethorphan and cocaine and another from heroin and methadone). The PCM condition had two non-study-related deaths (one from pneumonia and one from methadone overdose). There were 59 non-studyrelated hospitalizations in TAU and 67 in PCM.
Additional planned analyses
Because it is important to examine changes in outcomes during the entire course of 12 months' treatment (and not just at one point), as shown in Table 4 , we examined the treatment condition × time interaction effects and found no significant difference between conditions for the primary outcome of the percentage of participants with opioid-positive urine screens, nor for any of the secondary outcomes.
DISCUSSION
This random assignment study tested the hypothesis that modifying rules associated with patient/staff conflict and relieving counselors of their disciplinary role to increase therapeutic alliance would result in higher rates of retention in treatment and fewer opioid-positive urine screens compared to usual care. What we found was surprising. There were no significant differences in opioid-positive urine screens, and with the sole exception of global qualify of life, no significant differences in any secondary outcomes. Participants in both conditions improved to approximately the same degree on all measures. However, from another perspective, eliminating mandated attendance at counseling sessions did not appear to produce a lesser degree of improvement. This finding supports results from a previous randomized trial conducted in Texas among newly admitted MTP patients that found no significant between-group differences in 12-month retention or drug use between optional versus required counseling groups [36] . It is likely that changes in overall social context of opioid treatment in Baltimore may explain the lack of difference in treatment retention, opioid-positive urine screens and other patient outcomes between treatment conditions. During the year prior to participant enrollment and continuing throughout the study, MTP waiting lists largely ceased to exist in Baltimore. This was due primarily to increases in government insurance coverage for many previously uninsured patients, which led to the opening of new private MTPs and permitted existing programs to increase their patient census without depending on limited grant funds. In addition, in Baltimore buprenorphine treatment became increasingly available [37] , serving as an alternative for patients leaving methadone treatment. Without a long list of people seeking treatment, and with greater dependence on income from insured patients, program management may have become more reluctant to discharge patients who did not meet program expectations about counseling adherence and negative urine screens. This was in sharp contrast to findings from our six-clinic study of Baltimore MTPs conducted between 2004 and 2007, which found that 40.5% of the patients discharged from treatment during the first 12 months left due to 'program-related reasons', including missing counseling or medication visits, not paying fees, continued drug use and providing an adulterated urine specimen [20] . While retention in the original MTP in the present study was Table 4 Tests of significance, P-values and estimated marginal means [95% confidence intervals (CIs)] for outcome variables at baseline, 3-, 6-and 12-month follow-up for treatment condition × time interaction (n = 295). 47% (140 of 295), 78% (189 of 243) of participants interviewed at the 12-month follow-up reported being enrolled in some treatment with methadone or buprenorphine. A reasonable explanation for this finding is that, with no waiting lists, patients with insurance could transfer to other programs that were more convenient or where they could escape from staff-patient conflict at the initial program. Also, unlike many other US jurisdictions [22] , prior to the start of the study the Baltimore City Detention Center began to continue methadone for detainees enrolled into an MTP at the time of arrest. This permitted detained patients to return to their treatment programs following release without interruption. The US methadone maintenance regulations formulated in 1972 have remained largely unchanged in terms of requiring counseling and the level of financial support for MTPs became linked closely to the provision of counseling. In addition, in the United States, most MTP practitioners came to believe that counseling was such an essential element of the treatment that participation was generally made mandatory. Failure to attend became a point of program-patient conflict and persistent nonparticipation became a justification for discharge from treatment [20] , in contrast to other countries, including the United Kingdom [38] and Australia [39] , where methadone is provided frequently through primary care and counseling is not mandatory. This study's findings do not support the view that mandated counseling is needed to obtain improvement among MTP patients during the first year of treatment. Patients in PCM afforded the option of attending individual and/or group counseling attended as many individual sessions as participants in TAU. Group counseling was attended less frequently by PCM than TAU participants (although not significantly). The clinical implication is that, although some patients may benefit from mandatory counseling for particular issues, setting rules requiring all patients to receive counseling during the first year of methadone treatment may not be associated with superior outcomes.
Strengths and limitations
This study had a number of strengths, including random assignment, high ascertainment and follow-up rates, use of measures with known psychometric properties and an objective measure of drug use. Urine drug test results did not differ between the dipstick screenings or laboratory results (the former were presented because when the laboratory changed ownership, it discarded a number of specimens without testing them). It is not known if we would have had different results had we used hair testing rather than urine testing [40] . Because participants were predominantly older African Americans, most of whom were unemployed, it is not clear to what degree findings from this study can be generalized to other MTP populations. Finally, Baltimore, with virtually no waiting lists for entry to opioid treatment at the time of the study, may have led to a change in program responses to rule infractions in TAU to resemble PCM more closely (except for optional counseling), and may not be typical of other localities in the United States with waiting lists [41] .
Our findings suggest that requiring counseling is not demonstrably better than allowing patients to choose how much individual or group counseling they find 12-month means do not correspond to means in Table 3 because means in Table 4 are estimated marginal means from GEE analyses. DSM-IV opioid and cocaine dependence were analysed at baseline and 12 months only because their criteria are measured over a 12-month period. The relatively high rate of meeting these criteria at 12-month follow-up could have been influenced by meeting criteria in the first few months of treatment. Due to missing urine samples, the ns for opioid and cocaine urine screens are as follows: at baseline, n = 292 (three missing); at 3-month follow-up, n = 254 (12 missing); at 6-month follow-up, n = 244 (11 missing) for opioid and 245 ( valuable. Whether these findings can have an influence on the behavior of counseling staff, many of whom believe that patients will not change behavior without some coercion, or on accreditation bodies or regulatory agencies, is uncertain. Currently in the United States, funding of treatment is entwined intricately in a package of services that includes supervised methadone administration, drug testing and evidence of counseling attendance. Any changes in this package will require re-thinking the essential elements of MTPs and how these elements should be reimbursed.
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